4,087 Shares in Elevance Health, Inc. $ELV Acquired by Solidarity Wealth LLC

Key Points

• Solidarity Wealth LLC opened a new position in Elevance Health, buying 4,087 shares worth about $1.43 million, while hedge funds and other institutional investors collectively own roughly 89.24% of the stock.
• Elevance beat Q1 estimates (EPS $12.58 vs. $10.74), raised its 2026 adjusted EPS outlook to at least $26.75, and is targeting about 12% EPS growth in 2027, signaling stronger-than-expected earnings momentum.
• Analyst responses are mixed—price targets range from about $350 (Mizuho) to $424 (Sanford C. Bernstein)—and MarketBeat shows a consensus rating of Hold with an average price target of $380.42.

Solidarity Wealth LLC acquired a new position in Elevance Health, Inc. (NYSE:ELV - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 4,087 shares of the company's stock, valued at approximately $1,433,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Murphy Middleton Hinkle & Parker Inc. purchased a new position in Elevance Health during the fourth quarter valued at approximately $5,941,000. Evergreen Wealth Management LLC lifted its holdings in Elevance Health by 33.5% during the third quarter. Evergreen Wealth Management LLC now owns 17,283 shares of the company's stock valued at $5,584,000 after purchasing an additional 4,336 shares in the last quarter. Blume Capital Management Inc. lifted its holdings in Elevance Health by 236.7% during the third quarter. Blume Capital Management Inc. now owns 6,145 shares of the company's stock valued at $1,986,000 after purchasing an additional 4,320 shares in the last quarter. Canoe Financial LP lifted its holdings in Elevance Health by 18.1% during the third quarter. Canoe Financial LP now owns 389,399 shares of the company's stock valued at $125,823,000 after purchasing an additional 59,743 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its holdings in Elevance Health by 31.1% during the third quarter. Victory Capital Management Inc. now owns 461,693 shares of the company's stock valued at $149,182,000 after purchasing an additional 109,462 shares in the last quarter. Hedge funds and other institutional investors own 89.24% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ELV. Mizuho lowered their price target on shares of Elevance Health from $413.00 to $350.00 and set an "outperform" rating on the stock in a report on Wednesday, March 11th. Jefferies Financial Group decreased their target price on Elevance Health from $395.00 to $391.00 and set a "buy" rating on the stock in a research note on Monday. Weiss Ratings downgraded Elevance Health from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Monday, February 2nd. Wolfe Research set a $425.00 target price on Elevance Health and gave the company an "outperform" rating in a research note on Thursday, January 8th. Finally, JPMorgan Chase & Co. lifted their target price on Elevance Health from $394.00 to $397.00 and gave the company an "overweight" rating in a research note on Monday, February 2nd. Eleven research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $380.42.

Elevance Health News Summary

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q1 beat and upgraded outlook — ELV reported strong Q1 results (EPS $12.58 vs. estimates) and raised its 2026 adjusted EPS outlook to at least $26.75 while targeting ~12% EPS growth in 2027, which supports earnings upside and margin improvement. Elevance raises 2026 outlook
• Positive Sentiment: Large analyst upgrade — Sanford C. Bernstein raised its price target to $424 and kept an "outperform" rating, implying ~23% upside; a high-conviction bullish call that can attract demand. Bernstein raises PT to $424
• Positive Sentiment: Barclays reiteration of Buy — Barclays stuck with a Buy rating, signaling institutional confidence that can provide support for the shares. Barclays sticks to Buy
• Positive Sentiment: Operational tailwinds noted — Management highlighted medical cost controls and AI-driven margin expansion, and major outlets reported the company raised its annual profit forecast on those controls, reinforcing the positive earnings message. Profit forecast raised on cost controls
• Neutral Sentiment: Mixed analyst PT lifts with conservative ratings — Several firms nudged up targets but kept neutral/hold stances (Goldman to $370 neutral; Deutsche Bank to $363 hold; Evercore to $360 in-line). These raise reference prices but signal measured optimism. Goldman raises PT to $370
• Neutral Sentiment: Jefferies update — Jefferies revised its forecasts after a deeper look at exchange-segment dynamics and trimmed its PT slightly; this is an analyst reshuffle rather than a directional shock. Jefferies updates forecasts
• Negative Sentiment: Investor litigation probe — Law firm Kirby McInerney has opened an investigation into potential securities claims involving Elevance and/or its senior management; legal scrutiny can pressure the stock and raise uncertainty. Kirby McInerney investor alert
• Negative Sentiment: Some broker nuance implies limited near-term upside — Robert W. Baird's update leaves a neutral stance with a lower relative target vs. some peers, noting limited immediate upside which can cap buying interest. Baird adjusts PT

Elevance Health Price Performance

NYSE:ELV opened at $344.64 on Friday. The company has a current ratio of 1.48, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $74.84 billion, a P/E ratio of 14.66, a P/E/G ratio of 1.84 and a beta of 0.49. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $427.54. The business's 50-day moving average is $308.96 and its 200 day moving average is $331.62.

Elevance Health (NYSE:ELV - Get Free Report) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $10.74 by $1.84. The company had revenue of $49.49 billion for the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. Elevance Health's revenue was up 1.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, equities research analysts forecast that Elevance Health, Inc. will post 26.79 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a yield of 2.0%. Elevance Health's dividend payout ratio is presently 27.39%.

About Elevance Health

Elevance Health, Inc NYSE: ELV is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company's strategic focus on integrated health care and benefit delivery.

Elevance's core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.